TDENV LAV

Drug Profile

TDENV LAV

Alternative Names: Dengue vaccine live - GlaxoSmithKline; T-DEN F-19; T-DEN F17; TDENV-LAV F17; Tetravalent dengue live attenuated virus formulation 17; WRAIR Live Attenuated Tetravalent Dengue Vaccine

Latest Information Update: 20 Apr 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator GlaxoSmithKline
  • Developer GlaxoSmithKline; Oswaldo Cruz Foundation; Walter Reed Army Institute of Research
  • Class Dengue vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Dengue

Most Recent Events

  • 05 Apr 2017 GlaxoSmithKline withdraws a phase I trial in Dengue (prevention) prior to enrolment in USA (NCT03110952)
  • 18 Jun 2013 Discontinued - Phase-I/II for Dengue (prevention, in adults) in Thailand (SC)
  • 18 Jun 2013 Discontinued - Phase-I/II for Dengue (prevention, in children) in Thailand (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top